全文获取类型
收费全文 | 36975篇 |
免费 | 5517篇 |
国内免费 | 810篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 1227篇 |
妇产科学 | 432篇 |
基础医学 | 4018篇 |
口腔科学 | 91篇 |
临床医学 | 2967篇 |
内科学 | 939篇 |
皮肤病学 | 137篇 |
神经病学 | 103篇 |
特种医学 | 1486篇 |
外国民族医学 | 74篇 |
外科学 | 4739篇 |
综合类 | 4718篇 |
现状与发展 | 6篇 |
一般理论 | 1篇 |
预防医学 | 2177篇 |
眼科学 | 37篇 |
药学 | 2187篇 |
28篇 | |
中国医学 | 657篇 |
肿瘤学 | 17268篇 |
出版年
2024年 | 43篇 |
2023年 | 566篇 |
2022年 | 830篇 |
2021年 | 1828篇 |
2020年 | 1800篇 |
2019年 | 1588篇 |
2018年 | 1507篇 |
2017年 | 1557篇 |
2016年 | 1703篇 |
2015年 | 2048篇 |
2014年 | 2504篇 |
2013年 | 2769篇 |
2012年 | 2060篇 |
2011年 | 2207篇 |
2010年 | 1706篇 |
2009年 | 1620篇 |
2008年 | 1630篇 |
2007年 | 1754篇 |
2006年 | 1753篇 |
2005年 | 1611篇 |
2004年 | 1344篇 |
2003年 | 1284篇 |
2002年 | 1085篇 |
2001年 | 946篇 |
2000年 | 759篇 |
1999年 | 642篇 |
1998年 | 471篇 |
1997年 | 456篇 |
1996年 | 376篇 |
1995年 | 362篇 |
1994年 | 304篇 |
1993年 | 253篇 |
1992年 | 215篇 |
1991年 | 204篇 |
1990年 | 161篇 |
1989年 | 141篇 |
1988年 | 140篇 |
1987年 | 133篇 |
1986年 | 131篇 |
1985年 | 142篇 |
1984年 | 123篇 |
1983年 | 87篇 |
1982年 | 122篇 |
1981年 | 102篇 |
1980年 | 57篇 |
1979年 | 57篇 |
1978年 | 41篇 |
1977年 | 29篇 |
1976年 | 25篇 |
1975年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的:构建预测年轻乳腺癌患者生存情况的列线图,以期帮助临床诊疗。方法:收集SEER数据库中5 525例年轻乳腺癌患者的临床信息,通过单因素Log-rank检验和多因素Cox生存分析筛选出独立预后因素,用于构建预测患者3、5年总生存率(overall survival,OS)和癌症特异性生存率(cancer special survival,CSS)的列线图,将我院就诊的147例年轻乳腺癌患者作为验证集进行外部验证。结果:单因素和多因素分析结果显示,种族、病理类型、组织学分级、T分期、N分期、M分期、ER状态、HER-2状态、手术方式是与患者OS和CSS相关的独立危险因素,将这些因素纳入并建立预测患者OS和CSS的列线图模型。内部和外部验证结果显示模型具有良好的预测性能。基于建立的OS和CSS列线图模型对患者进行了风险分层,能够准确地将年轻乳腺癌患者分成预后有显著差异的三个风险亚组。结论:本研究构建的预测模型能较为准确的预测年轻乳腺癌患者的预后情况,为临床的诊疗提供科学依据。 相似文献
2.
Kely Paviani StevanatoRaíssa Bocchi PedrosoCatia Millene Dell AgnoloLander Dos SantosFernando Castilho PellosoMaria Dalva de Barros CarvalhoSandra Marisa Pelloso 《Asian Pacific journal of cancer prevention》2022,23(4):1117-1123
Objective: To perform a scoping review of the applicability of the Gail model in different countries for different ethnicities. Methods: The review was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist and search strategies based on the PICOS approach. The reviewed articles were included if they were published between 2013 and 2018 in English, Portuguese, or Spanish; were original articles available in full online; and described the use of the Gail model. The PubMed, Embase, and Web of Science data bases were searched. Results: A total of 38 articles eligible for analysis were identified, of which 16 used the Gail model to assess breast cancer risk in women, eight analyzed the applicability of this tool in their population, seven compared the tool and/or modified it according to the specific risk factors of their population, and seven cited the model in determining eligibility for chemoprevention. Conclusion: The Gail model has different applicabilities Greater effectiveness and breast cancer risk are found in developed countries. 相似文献
3.
《Value in health》2022,25(1):69-76
ObjectivesThere is limited knowledge about the cost patterns of patients who receive a diagnosis of de novo and recurrent advanced cancers in the United States.MethodsData on patients who received a diagnosis of de novo stage IV or recurrent breast, colorectal, or lung cancer between 2000 and 2012 from 3 integrated health systems were used to estimate average annual costs for total, ambulatory, inpatient, medication, and other services during (1) 12 months preceding de novo or recurrent diagnosis (preindex) and (2) diagnosis month through 11 months after (postindex), from the payer perspective. Generalized linear regression models estimated costs adjusting for patient and clinical factors.ResultsPatients who developed a recurrence <1 year after their initial cancer diagnosis had significantly higher total costs in the preindex period than those with recurrence ≥1 year after initial diagnosis and those with de novo stage IV disease across all cancers (all P < .05). Patients with de novo stage IV breast and colorectal cancer had significantly higher total costs in the postindex period than patients with cancer recurrent in <1 year and ≥1 year (all P < .05), respectively. Patients in de novo stage IV and those with recurrence in ≥1 year experienced significantly higher postindex costs than the preindex period (all P < .001).ConclusionsOur findings reveal distinct cost patterns between patients with de novo stage IV, recurrent <1-year, and recurrent ≥1-year cancer, suggesting unique care trajectories that may influence resource use and planning. Future cost studies among patients with advanced cancer should account for de novo versus recurrent diagnoses and timing of recurrence to obtain estimates that accurately reflect these care pattern complexities. 相似文献
4.
5.
《Diagnostic Histopathology》2022,28(3):156-160
Breast core biopsies are a standard component of the triple approach that includes clinical examination, imaging and tissue sampling. Conventional cores, diagnostic vacuum assisted biopsy and vacuum assisted excisions are established methods for sampling and managing breast lesions. It is important to be aware of the potential pitfalls in the technical handling and interpretation of the limited core biopsy samples. Here, we present a clinically oriented, well illustrated overview of the common diagnostic pitfalls based on the author's diagnostic and second opinion practice, emphasize the value of clinicopathological correlation and provide histological tips and clues with useful immunohistochemistry to aid the reporting pathologists in their daily interpretation of breast core biopsies. 相似文献
6.
Tomoe Koizumi PhD Yodo Sugishita MD PhD Yuki Suzuki-Takahashi MD PhD Kazuko Nara MA Tomoko Miyagawa MA Misako Nakajima MA Kouhei Sugimoto MD PhD Manabu Futamura MD PhD Tatsuro Furui MD PhD Yasushi Takai MD PhD Hiroshi Matsumoto MD PhD Hideko Yamauchi MD Shinji Ohno MD PhD Akemi Kataoka MD PhD Kiyotaka Kawai MD PhD Eisuke Fukuma MD PhD Hiroko Nogi MD PhD Koichiro Tsugawa MD PhD Nao Suzuki MD PhD 《Cancer》2023,129(16):2568-2580
7.
《The Journal for Nurse Practitioners》2022,18(2):140-146
Early detection and improved treatments for breast cancer are increasing survival rates, thereby growing the number of survivors to almost 4 million in the United States. Continuing care after treatment is frequently provided in primary care. Evidence-based care includes a history review, physical examination, and imaging for recurrence and new cancers, along with health maintenance and health promotion. Additionally, survivors often experience long-term side effects from their disease and/or treatment, affecting health and quality of life. This article provides a synopsis of breast cancer treatment-related side effects and current evidence-based guidelines to assist the primary care provider caring for survivors. 相似文献
8.
9.
10.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献